Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Byung-Joon Kim  (Kim BJ) 2 Articles
Clinical Study
Effects of Short-Term Exenatide Treatment on Regional Fat Distribution, Glycated Hemoglobin Levels, and Aortic Pulse Wave Velocity of Obese Type 2 Diabetes Mellitus Patients
Ju-Young Hong, Keun-Young Park, Byung-Joon Kim, Won-Min Hwang, Dong-Ho Kim, Dong-Mee Lim
Endocrinol Metab. 2016;31(1):80-85.   Published online March 16, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.1.80
  • 4,905 View
  • 45 Download
  • 26 Web of Science
  • 22 Crossref
AbstractAbstract PDFPubReader   
Background

Most type 2 diabetes mellitus patients are obese and have obesity related vascular complications. Exenatide treatment is well known for both decreasing glycated hemoglobin levels and reduction in body weight. So, this study aimed to determine the effects of exenatide on body composition, glycated hemoglobin levels, and vascular stiffness in obese type 2 diabetes mellitus patients.

Methods

For 1 month, 32 obese type 2 diabetes mellitus patients were administered 5 µg of exenatide twice daily. The dosage was then increased to 10 µg. Patients' height, body weight, glycated hemoglobin levels, lipid profile, pulse wave velocity (PWV), body mass index, fat mass, and muscle mass were measured by using Inbody at baseline and after 3 months of treatment.

Results

After 3 months of treatment, glycated hemoglobin levels decreased significantly (P=0.007). Triglyceride, total cholesterol, and low density lipoprotein levels decreased, while aspartate aminotransferase and alanine aminotransferase levels were no change. Body weight, and fat mass decreased significantly (P=0.002 and P=0.001, respectively), while interestingly, muscle mass did not decrease (P=0.289). In addition to, Waist-to-hip ratio and aortic PWV decreased significantly (P=0.006 and P=0.001, respectively).

Conclusion

Effects of short term exenatide use in obese type 2 diabetes mellitus with cardiometabolic high risk patients not only reduced body weight without muscle mass loss, body fat mass, and glycated hemoglobin levels but also improved aortic PWV in accordance with waist to hip ratio.

Citations

Citations to this article as recorded by  
  • Adipose tissue inflammation linked to obesity: A review of current understanding, therapies and relevance of phyto-therapeutics
    Christiana Eleojo Aruwa, Saheed Sabiu
    Heliyon.2024; 10(1): e23114.     CrossRef
  • Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32‐week randomized trial
    Liv Vernstrøm, Søren Gullaksen, Steffen S. Sørensen, Kristian L. Funck, Esben Laugesen, Per L. Poulsen
    Diabetes, Obesity and Metabolism.2024;[Epub]     CrossRef
  • Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes
    Daniel de Luis Román, Juana Carretero Gómez, José Manuel García-Almeida, Fernando Garrachón Vallo, German Guzmán Rolo, Juan José López Gómez, Francisco José Tarazona-Santabalbina, Alejandro Sanz-Paris
    Reviews in Endocrine and Metabolic Disorders.2024;[Epub]     CrossRef
  • The Current Landscape of Pharmacotherapies for Sarcopenia
    Gulistan Bahat, Serdar Ozkok
    Drugs & Aging.2024; 41(2): 83.     CrossRef
  • Vascular Aging: Assessment and Intervention
    Ao Li, Jinhua Yan, Ya Zhao, Zhenping Yu, Shane Tian, Abdul Haseeb Khan, Yuanzheng Zhu, Andong Wu, Cuntai Zhang, Xiao-Li Tian
    Clinical Interventions in Aging.2023; Volume 18: 1373.     CrossRef
  • The Effect of Additional Treatment with Empagliflozin or Semaglutide on Endothelial Function and Arterial Stiffness in Subjects with Type 1 Diabetes Mellitus—ENDIS Study
    Maja Preložnik Navodnik, Andrej Janež, Ivan Žuran
    Pharmaceutics.2023; 15(7): 1945.     CrossRef
  • Sarcopenia as a Little-Recognized Comorbidity of Type II Diabetes Mellitus: A Review of the Diagnosis and Treatment
    Christian Salom Vendrell, Elisa García Tercero, Juan Bautista Moro Hernández, Bernardo Abel Cedeno-Veloz
    Nutrients.2023; 15(19): 4149.     CrossRef
  • Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
    Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Valentina Lavarra, Domenico Triggiani, Lucilla Crudele, Vincenzo Triggiani, Carlo Sabbà, Giovanni De Pergola, Giuseppina Piazzolla
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
    Sydney S. Wilbon, Mikhail G. Kolonin
    Cells.2023; 13(1): 65.     CrossRef
  • The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
    Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata
    Medicines.2022; 9(9): 47.     CrossRef
  • Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
    Juan J. Gorgojo-Martínez, Pedro Mezquita-Raya, Juana Carretero-Gómez, Almudena Castro, Ana Cebrián-Cuenca, Alejandra de Torres-Sánchez, María Dolores García-de-Lucas, Julio Núñez, Juan Carlos Obaya, María José Soler, José Luis Górriz, Miguel Ángel Rubio-H
    Journal of Clinical Medicine.2022; 12(1): 145.     CrossRef
  • The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms
    Elena Massimino, Anna Izzo, Gabriele Riccardi, Giuseppe Della Pepa
    Cells.2021; 10(8): 1958.     CrossRef
  • Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications
    Xueli Zhang, Yi Zhao, Shuobing Chen, Hua Shao
    Journal of Cachexia, Sarcopenia and Muscle.2021; 12(6): 1368.     CrossRef
  • Effect of glycemic control on markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus: A review
    Sofia Antoniou, Katerina K K Naka, Marios Papadakis, Aris Bechlioulis, Agathocles Tsatsoulis, Lampros K Michalis, Stelios Tigas
    World Journal of Diabetes.2021; 12(11): 1856.     CrossRef
  • A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
    Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies
    Endocrinology and Metabolism.2019; 34(3): 247.     CrossRef
  • The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis
    Takahiro Yajima, Kumiko Yajima, Hiroshi Takahashi, Keigo Yasuda
    Journal of Diabetes and its Complications.2018; 32(8): 759.     CrossRef
  • Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis
    Konstantinos Batzias, Alexios S. Antonopoulos, Evangelos Oikonomou, Gerasimos Siasos, Evanthia Bletsa, Panagiota K. Stampouloglou, Chara-Vasiliki Mistakidi, Marina Noutsou, Niki Katsiki, Periklis Karopoulos, Georgios Charalambous, Anastasia Thanopoulou, N
    Journal of Diabetes Research.2018; 2018: 1.     CrossRef
  • Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes
    N. González, Z. Moreno-Villegas, A. González-Bris, J. Egido, Ó. Lorenzo
    Cardiovascular Diabetology.2017;[Epub]     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Difference in protective effects of GIP and GLP-1 on endothelial cells according to cyclic adenosine monophosphate response
    Dong-Mee Lim, Keun-Young Park, Won-Min Hwang, Ju-Young Kim, Byung-Joon Kim
    Experimental and Therapeutic Medicine.2017; 13(5): 2558.     CrossRef
  • Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists
    Qiuhe Ji
    Clinical Therapeutics.2017; 39(6): 1244.     CrossRef
  • Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications
    Almudena Gómez-Hernández, Nuria Beneit, Sabela Díaz-Castroverde, Óscar Escribano
    International Journal of Endocrinology.2016; 2016: 1.     CrossRef
Close layer
Adrenal gland
Genetic Analysis of Multiple Endocrine Neoplasia Type 1 (MEN1) Leads to Misdiagnosis of an Extremely Rare Presentation of Intrasellar Cavernous Hemangioma as MEN1
Dong Min Lee, Seung Hee Yu, Hyun Hwa Yoon, Kang Lock Lee, Young Sil Eom, Kiyoung Lee, Byung-Joon Kim, Yeun Sun Kim, Ie Byung Park, Kwang-Won Kim, Sihoon Lee
Endocrinol Metab. 2014;29(2):146-153.   Published online June 26, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.2.146
  • 3,730 View
  • 37 Download
  • 1 Web of Science
  • 2 Crossref
AbstractAbstract PDFPubReader   
Background

Multiple endocrine neoplasia type 1 (MEN1) is a rare inherited disorder characterized by the simultaneous occurrence of endocrine tumors in target tissues (mainly the pituitary, endocrine pancreas, and parathyroid glands). MEN1 is caused by mutations in the MEN1 gene, which functions as a tumor suppressor and consists of one untranslated exon and nine exons encoding the menin protein. This condition is usually suspected when we encounter patients diagnosed with tumors in multiple endocrine organs, as mentioned above.

Methods

A 65-year-old woman who underwent surgery for a pancreatic tumor (serous cystadenoma) 5 years previously was referred to our hospital due to neurologic symptoms of diplopia and left ptosis. Brain magnetic resonance imaging revealed a 3.4-cm lesion originating from the cavernous sinus wall and extending into the sellar region. It was thought to be a nonfunctioning tumor from the results of the combined pituitary function test. Incidentally, we found that she also had a pancreatic tumor, indicating the necessity of genetic analysis for MEN1.

Results

Genomic analysis using peripheral leukocytes revealed a heterozygous c.1621G>A mutation in the MEN1 gene that was previously reported to be either a pathogenic mutation or a simple polymorphism. We pursued a stereotactic approach to the pituitary lesion, and microscopic findings of the tumor revealed it to be an intrasellar cavernous hemangioma, a rare finding in the sellar region and even rarer in relation to oculomotor palsy. The patient recovered well from surgery, but refused further evaluation for the pancreatic lesion.

Conclusion

There is great emphasis placed on genetic testing in the diagnosis of MEN1, but herein we report a case where it did not assist in diagnosis, hence, further discussion on the role of genetic testing in this disease is needed. Also, in cases of pituitary tumor with cranial nerve palsy, despite its low prevalence, intrasellar cavernous hemangioma could be suspected.

Citations

Citations to this article as recorded by  
  • Diffuse cavernous hemangioma of the skull misdiagnosed as skull metastasis in breast cancer patient: one case report and literature review
    Huizhi Liu, Xiaojing Chang, Hua Shang, Feng Li, Huandi Zhou, Xiaoying Xue
    BMC Cancer.2019;[Epub]     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism